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Abstract 31 
Currently, there is a need for reliable tests that allow identification of individuals that have been 32 
infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority 33 
of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of 34 
antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or 35 
the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses. 36 
Conceivably, exposure of antigens released from infected cells could stimulate antibody 37 
responses that might correlate with tissue damage and, hence, they may have some value as 38 
a prognostic indicator. We addressed whether other non-structural viral proteins, not 39 
incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might 40 
also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins 41 
produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA 42 
antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or 43 
Mpro, and it can be used to identify individuals with positive serology against the coronavirus. 44 
Higher antibody titres in these assays associated with more severe disease and no cross-45 
reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies 46 
specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In 47 
conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests 48 
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INTRODUCTION 55 
The identification of the link between a novel beta-coronavirus strain, named 56 
Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2), and a fatal 57 
respiratory illness, COVID-19, formally recognised as a pandemic by the WHO on 58 
March 11 (1, 2) has led to a rush by health systems all over the world to develop and 59 
implement testing for viral infection. The rapid cloning and sequencing of the viral 60 
genome permitted the development of PCR-based assays for the detection of viral 61 
nucleic acids that have become a key strategy for both clinical diagnosis and 62 
epidemiological monitoring studies. However, besides identifying individuals with 63 
active infection, it is also necessary to know which patients, either symptomatic or 64 
asymptomatic, have developed an antibody response to the virus. Several reasons 65 
make SARS-CoV-2 serology tests crucial. First, PCR testing is not 100% efficient, (3-66 
5). Second, testing for viral RNA cannot detect evidence of past infection, which will 67 
be crucial for epidemiological efforts to assess how many people have been infected 68 
in any given area. In addition, this will allow definition of the infection fatality rate and 69 
help with management of the epidemic.  Third, assays to measure antibody responses 70 
and determine seroconversion, while not appropriate to detect acute infections, are 71 
however, valuable sources of information on the quality of the response exerted by 72 
different individuals developing different clinical manifestations. Moreover, if different 73 
isotypes and viral antigens are included in assays testing different time points after the 74 
onset of the disease, information of clinical importance will be produced. Finally, 75 
quantitative and qualitative assays of antibody responses can aid in the identification 76 
of factors that correlate with effective immunity to SARS-CoV-2, the duration of these 77 
immune responses and may also aid in the selection of donors from whom 78 
preparations of convalescent serum/plasma can be generated for therapeutic use. 79 
Multiple antibody tests to detect exposure to SARS-CoV-2, are becoming available. 80 
The majority of these assays have been optimised to detect immunoglobulin G (IgG) 81 
and, in some cases, IgM antibodies using different viral antigens, being the Spike (S) 82 
protein and the nucleoprotein of SARS-CoV-2 the more widely used (6, 7). These 83 
proteins are key elements of the viral particle and are expected, by analogy with other 84 
coronaviruses, to be highly immunogenic. However, the immunogenicity of other viral 85 
proteins, 28 are encoded in the viral genome, has been little explored. Here we have 86 
studied the antibody response to the main viral protease (Mpro, or 3CLPro) elicited 87 
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after viral infection. Although this protein is not exposed in the viral particle, Mpro 88 
carries out a critical role in viral replication. Like other beta-coronaviruses, SARS-CoV-89 
2 is a positive-sense RNA virus that expresses all of its proteins as a single polypeptide 90 
chain and Mpro cleaves the 1ab polyprotein to yield the rest of the mature proteins of 91 
the virus. Since this activity is essential for the viral life cycle, Mpro structure and 92 
function has been studied intensively (8); in particular, Mpro has been suggested as a 93 
target for specific inhibitors that might act as potent anti-viral agents (9). However, to 94 
our knowledge, no study on the antigenicity of this protease has been reported. 95 
To increase the possibilities of diagnosing COVID-19 patients, here we report the 96 
use of an ELISA test involving the assay of sero-reactivity to three different SARS-97 
CoV-2 antigens, including the protease Mpro. These data demonstrate that individuals 98 
who have been infected with SARS-CoV-2 make high titre antibody responses to Mpro 99 
and that assays for seroreactivity to this protein sensitively and specifically 100 
discriminate between infected and non-infected individuals. Further, while most 101 
available tests assess for SARS-CoV-2-specific IgM and IgG antibodies, here, we also 102 
explored the presence of IgA antibodies in the sera tested. While, in general, assays 103 
for IgM antibodies resulted in a high background that limited the sensitivity of the 104 
ELISA, testing for IgA seropositivity provided very clean data, with low background 105 
and high signal, therefore providing a very good tool to complement IgG assays.  106 
Interestingly, considerable significant amounts of IgA antibodies specific for MPro, as 107 
well as the Receptor Binding Domain (RBD) and NP, were also frequently found in 108 
serum of COVID-19 infected individuals and the amounts of IgA and IgM antibodies 109 
could be related with disease severity. 110 
Surprisingly, IgG antibodies specific for SARS-CoV-2 antigens were also readily 111 
detectable in the saliva of these patients and, in this case, the titre of protease-specific 112 
antibodies was higher than for the other two proteins tested. Since the nasal and 113 
buccal mucosa are key sites of viral infection and replication, the presence of 114 
antibodies in saliva may be an important feature of the virus-specific immune 115 
response, but this observation may also allow the development of a rapid, completely 116 
non-invasive assay for COVID-19 seropositivity.  117 
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RESULTS 118 
 119 
Mpro-specific antibodies can be detected in serum of COVID-19 patients by ELISA  120 
Since this study evaluated, for the first time, whether coronavirus-infected individuals could 121 
generate an antibody response against the Cys-like protease, MPro, other SARS-CoV-2 122 
proteins, commonly used in serology tests, were produced, for comparison. Mpro and NP were 123 
expressed in E coli, and two different constructs of the Receptor Binding Domain (RBD) of the 124 
spike protein were used: one was expressed by transfection in mammalian cells (mRBD) and 125 
a second, produced by baculovirus infection of insect cells (iRBD-His). All the proteins, except 126 
mRBD, had a histidine-tag and they were purified on Ni2+-NTA columns followed by size 127 
exclusion chromatography (Figure 1).  128 
 129 
Before testing a large number of sera from COVID-19 patients and healthy donors, 130 
experiments were designed to optimize coating and dilution conditions. These data already 131 
revealed that COVID-19 patient sera contained high titres of Mpro-specific antibodies. 132 
Antibody reactivity to the viral protease reached saturation at relatively low concentrations and 133 
discriminated efficiently between individuals who had been infected with SARS-CoV-2 and 134 
those that had not been exposed to the virus (Figure 2A). Serum dilutions from 1/50 to 1/1600 135 
covered a broad range of reactivity to Mpro from almost no recognition to saturation (reached 136 
at 1/100 dilution). It was also possible to detect low titres of antibodies of the IgM and IgA 137 
isotypes in these patients (Figure 2B), suggesting that, in subsequent experiments, a large 138 
screening of patient samples should be performed including the three Ig subclasses. Coating 139 
titration experiments further confirmed the specificity of the assay (Figure 2C). The IgG 140 
reactivity against the protease MPro in COVID-19 patients was comparable, or in certain cases 141 
stronger, to the reactivity against RBD, however, no differences were noticed between the 142 
RBD recombinant proteins expressed in either mammalian cells or baculovirus 143 
(Supplementary Figure 1).  These initial experiments suggested that the humoral response 144 
against the three viral proteins can be heterogeneous between different patients. 145 
To further validate the assay, additional controls were performed such as monitoring the 146 
background in plates with no viral antigen coating and testing sera collected before the 147 
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Detection of SARS-CoV-2 Mpro-specific antibodies identifies COVID-19 seropositive 152 
individuals with high specificity and sensitivity  153 
A cohort of 36 COVID-19 patients (PCR+) and 33 healthy donors was recruited at La Princesa 154 
University Hospital, Madrid (Table 1) and ELISA assays were performed to detect Mpro-, as 155 
well as RBD- and NP-, specific antibodies of the IgG, IgA and IgM subclasses in sera (Figure 156 
3). 157 
Titration of the serum samples was carried out over a dilution range of 1/50 to1/3200, and these 158 
experiments showed that assay for seropositivity to all three antigens discriminated between 159 
COVID-19 positive and negative donors, as shown in dot plots comparing different dilutions 160 
(Supplementary Figure 3). Figure 3 summarises the absorbance data from all the sera samples. 161 
To estimate the cut-off value, the sensitivity, and the specificity parameters for each antigen/Ig 162 
isotype pair, receiver operating characteristic (ROC) analyses were performed (Table 2, Figure 4). 163 
The best area under the curve (AUC) values were obtained with the measurement of IgG 164 
antibodies specific for Mpro and NP (AUCs= 0.9945 and 0.9927, respectively). The sensitivity and 165 
specificity was above 90% for detection of IgG antibodies of the three proteins tested, with values 166 
of sensitivity and specificity for Mpro of 97% and 100% respectively. AUC values above 0.85 were 167 
obtained for the other isotypes (IgA, IgM). Measurement of anti-IgA antibodies appeared to 168 
discriminate less accurately between pre-COVID-19 sera and COVID-19 sera, however, this is not 169 
due to a lack in sensitivity for this isotype. Instead, because background levels with IgA were very 170 
low and the signal clearly positive in some patients, the lack of detection suggests that certain 171 
COVID-19-positive patients have circulating IgA while other COVID-19-positive patients lack IgA 172 
in peripheral blood. Whether the presence of IgA in periphery has any relationship with clinical 173 
aspects needs to be explored further in larger cohorts of patients. 174 
 175 
Comparison between proteins showed some heterogeneity in the capacity of different donors to 176 
produce antibodies, especially for IgM and IgA subclasses.  Non-linear polynomial regression 177 
showed a better correlation between the detection of antibodies against NP and Mpro compared 178 
to NP and RBD or MPro and RBD (Figure 5A). Only one COVID-19 donor failed to make a full 179 
antibody response. 180 
 181 
Further analyses were performed to explore the correlations between the titres of the different 182 
antibodies in serum and clinical parameters. Interestingly, a trend for higher titre antibody 183 
responses was found in patients with more severe disease (Figure 5B), being more pronounced 184 
for IgM against Mpro and IgG against RBD. However, several other variables also contributed to 185 
the heterogeneity in antibody response, mainly age and time since the onset of symptoms (Table 186 
3). After adjustment for these possibly confounding factors, IgA anti-RBD was observed to be 187 
significantly higher in critical patients compared to patients with mild disease. In addition, critical 188 
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patients showed a trend to higher IgM and IgA anti-Mpro titres than patients with mild COVID-19. 189 
Furthermore, intense IgM and IgA responses against the three proteins were significantly 190 
associated with higher serum IL-6 levels (data not shown). 191 
 192 
Importantly, in the experiments reported here no SARS-CoV-2-specific antibodies were detected 193 
in more than 70 serum samples collected pre-pandemic. However, the majority of these pre-194 
COVID-19 sera did contain antibodies against the nucleoprotein from the related HCoVOC43 195 
betacoronavirus, that causes mild common cold-like diseases (Figure 6). Thus these data 196 
demonstrate that prior infection with another coronavirus does not seem to lead to the generation 197 
of antibodies cross-reactive with the SARS-CoV-2 virus. 198 
 199 
Therefore, the use of SARS-CoV-2 Mpro, in combination with other antigens already described 200 
for serology tests, provided outstanding specificity and sensitivity for patient identification. IgG 201 
titrated further than IgA or IgM indicating that, as expected, the IgG subclass is more abundant 202 
in serum. Assay for IgM antibodies had a lower signal/noise ratio and, in many of the SARS-203 
CoV-2 negative sera a significant background could be observed for IgM. In contrast, SARS-204 
CoV-2-specific IgA antibodies were not detected in healthy donors, but were clearly present 205 
in 27 out of the 36 sera tested from COVID-19 patients.   206 
 207 
Mpro-specific IgG antibodies are detected in saliva from COVID-19 patients   208 
Saliva samples were collected from 11 healthy donors and 12 COVID-19 patients at the 209 
University Hospital La Princesa (Madrid) and tested in ELISA assays over a range of 210 
dilutions (1/2 to 1/10). IgG recognizing the three viral antigens tested could be observed in 211 
COVID-19 patients, with the strongest responses being those specific for the viral protease 212 
Mpro (Figure 7). IgA responses were detected in only one of the COVID-19 infected 213 
individuals (data not shown).  214 
  215 
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DISCUSSION  216 
The results presented here describe the detection of antibodies against the SARS-CoV-2 217 
protease, Mpro, in serum from COVID-19 patients. The titres of Mpro-specific antibodies were 218 
comparable to those produced against SARS-CoV-2 nucleoprotein and somewhat higher than 219 
the antibody responses to the RBD fragment of the Spike glycoprotein, both of which are 220 
generally considered immunogenic coronavirus proteins. These high titre antibody responses 221 
in serum were accompanied by the detection of Mpro-specific IgG antibodies in saliva, 222 
providing a new opportunity for completely, non-invasive diagnostic tests. 223 
For IgG antibodies in sera, the titres of NP and Mpro-specific antibodies correlate very well 224 
with each other (r=0.94 y p<10-4) and also with anti-RBD responses (r=0.89 y p<10-4). In 225 
contrast, while NP- and Mpro-specific antibody titres also correlate well for IgA and IgM 226 
responses (r values greater than 0.9), the correlation with IgM and IgA for RBD is much weaker 227 
(r values around 0.6). One plausible possibility is that the antibody responses to internal 228 
antigens, Mpro and NP, correlate well, since production of antibodies against these proteins 229 
requires either viruses with a broken membrane or release of viral material from infected cells.  230 
The correlation with clinical data and symptoms onset reveals that antibodies have higher 231 
titres as the severity of the disease increases. Although the sample size is not large, this 232 
correlation was significant and independent of age and time from the beginning of symptoms 233 
for anti-RBD IgA and almost significant for anti-Mpro IgM and IgA. The retrospective design of 234 
our study does not allow to determine whether these increased levels are cause or 235 
consequence of more severe disease and what is the basis of its relationship with higher levels 236 
of IL-6 detected in critical patients. In this regard, it is surprising that IgM persisted at high 237 
levels in patients’ sera for more than a month after the beginning of symptoms.    238 
The finding that the protease Mpro can be antigenic opens a new series of questions on the 239 
biology of this protein that is an important target for the development of antivirals to block 240 
SARS-CoV-2 replication. Mpro is key for cleavage and activation of the first polypeptide 241 
translated after infection, but the protein has not been found in the virion. So, most probably, 242 
the generation of antibodies directed against Mpro occurs at the end of the viral life cycle when 243 
intracellular antigens are released from the infected cell. It is not clear whether antibodies 244 
specific for Mpro might interfere with viral replication directly, however B cells producing these 245 
antibodies would likely efficiently internalise and present this antigen to stimulate T cell 246 
recognition of peptides from intracellular proteins. 247 
The data presented here also show that, while antibodies for another betacoronavirus, 248 
HCoVOC43, were found frequently in pre-COVID19 sera, SARS-Cov-2-specific antibodies were 249 
undetectable, demonstrating that infection with one coronavirus does not necessarily prime for a 250 
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better antibody response to another, at least for the viral antigens tested in these assays. 251 
Sequence analysis also suggests that it is unlikely that the response detected against NP and 252 
Mpro is due to cross-reactivity between coronavirus-specific antibodies. While COVID-19 Mpro 253 
has 96% homology with the main protease of SARS-CoV, which emerged in China in 2003, the 254 
similarity with other coronaviruses is much lower. All the samples analysed in this study came from 255 
hospitals in Spain, where no cases of SARS-CoV-1 have been reported. The similarity between 256 
the Cys-like proteases (Mpro) of different coronaviruses: SARS-CoV-2, HCovNL63, 257 
HCoVOC43 and HCov229E similarity is only around 40% with changes and similarities 258 
distributed along the whole sequence (Supplementary Figure 4).  259 
 260 
A remarkable observation is that SARS-CoV-2 specific antibodies can be detected in the saliva 261 
of seropositive individuals. Two major antibody classes are found in saliva: secretory IgA 262 
(SIgA), synthesized locally by plasma cells (PCs) in salivary glands and IgG that is mainly 263 
derived from serum via gingival crevices (10). In our experiments salivary SARs-CoV-2 264 
antibodies were mainly IgG rather than IgA; only one out of 12 individuals with SARS2-specific 265 
IgA was observed, corresponding to a donor that had recovered from the disease one month 266 
before the saliva test. The observation that COVID-19-positive, but not COVID-19-negative, 267 
individuals contain robustly detectable levels of SARS-CoV-2 NP and Mpro-specific antibodies 268 
in saliva is interesting because the development and validation of a saliva-based assay for 269 
SARS-CoV-2 seropositivity would represent a practical, non-invasive alternative to blood-270 
based assays for COVID-19 diagnostic testing that might complement saliva-based nucleic 271 
acid tests for SARS-CoV-2 nucleic acid.  272 
 273 
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METHODS 275 
Molecular cloning of the Cys-like protease (Mpro) and nucleocapsid (NP) proteins of 276 
SARS-CoV-2 and the NP of HCoV43 277 
A gene encoding SARS-CoV-2 Mpro from the Wuhan-Hu-1 strain (ORF1ab polyprotein 278 
residues 3264-3569, GenBank code:MN908947.3) was amplified by PCR using the oligos 5´-279 
gacccatggcttcagctgtttttcagagtggttt-3´ and 5´-gacctcgagttggaaagtaacacctgagcatt-3´, digested 280 
with NcoI and XhoI and ligated into the vector pET22b (Novagen) linearized with the same 281 
restriction enzymes.  282 
Oligonucleotides 5´-gatccatggcttctgataatggtccgcaaaatcagcgtaatgca-3´ and 5´-283 
caggtcgacaggctctgttggtgggaatg-3´were used to amplify the nucleocapsid protein of SARS-284 
CoV-2. The amplification product was then digested with NcoI and SalI and ligated into the 285 
pET26b vector (Novagen) digested with NcoI and XhoI. 286 
Oligonucleotides 5´- gatccatggtctcttttactcctggtaagcaatcc -3´ and 5´- 287 
gacctcgagtatttctgaggtgtcttcagtatag -3´were used to amplify the nucleocapsid protein of 288 
HCoVOC43. The amplification product was then digested with NcoI and XhoI and ligated into 289 
the pET26b vector (Novagen) digested with NcoI and XhoI. 290 
The integrity of all constructs was verified by sequencing at MWG Eurofins. 291 
Expression of the SARS-CoV-2 Cys-like protease (Mpro) and nucleocapsid (NP) 292 
proteins 293 
Recombinant viral proteins were expressed in the E. coli strain BL21 Star (DE3) pLysS 294 
(ThermoFisher).  295 
SARS-CoV-2 Mpro protein was expressed by transforming this plasmid into the E. coli 296 
strain BL21 Star (DE3) pLysS. Transformed clones were pre-cultured overnight at room 297 
temperature in 50 mL 1 x LB medium with ampicillin (150 μg/mL) and chloramphenicol 298 
(34ug/ml). The overnight culture was then inoculated into 1L of 1 x LB medium (150 μg/mL 299 
ampicillin and 34ug/ml chloramphenicol) and the culture was grown at 37oC with agitation until 300 
the OD600 reached 0.6 when Isopropyl-D-thiogalactoside (IPTG) was added to 1mM to induce 301 
overexpression of the Mpro gene. The same protocol was followed to produce the 302 
nucleocapsid proteins except that kanamycin (150ug/ml) was used instead of ampicillin for 303 
antibiotic-mediated selection. 304 
After overnight culture at 22oC for NP, 3h at 37oC for Mpro, bacteria were harvested 305 
by centrifugation at 9500 x g, 4°C for 15 min and the pellets were washed by resuspension in 306 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 18, 2020. .https://doi.org/10.1101/2020.07.16.20155853doi: medRxiv preprint 
150 mL TES buffer (20 mM Tris pH 8, 2mM EDTA, 150 mM NaCl) and re-centrifugation. 307 
Washed pellets were either processed immediately or stored frozen for later use. 308 
Fresh, or thawed, cell pellets were resuspended in ice.cold 50 mM NaH2PO4 buffer 309 
pH8, 500 mM NaCl, 10 mM imidazole (I2399, Sigma Aldrich), 0.1% Sarkosyl, and 5% glycerol 310 
(pH 8.0). Lysozyme was then added (to 0.25 mg/ml) as were phenylmethylsulfonyl fluoride, 311 
Leupeptin and Pepstatin A (all to a final concentration of 1mM) and DNase I (2 µg/ml). Bacteria 312 
were lysed by sonication (3 cycles of 30 seconds with 30 seconds rest on ice between pulses) 313 
and soluble proteins were separated by centrifugation of the lysed cells at 14,000g at 4 °C for 314 
45 minutes. 315 
6-histidine tagged proteins were purified from the lysate using Nickel Affinity Cartridges 316 
5ml (Agarose Bead Technologies S.L.). The bacterial supernatant was loaded on the column 317 
at a flow rate of 1 ml/min, followed by washing with 5 column volumes of 50 mM NaH2PO4 318 
buffer, 500 mM NaCl, 10 mM imidazole and then 5 column volumes of 50 mM NaH2PO4 buffer, 319 
500 mM NaCl, 25 mM imidazole. Recombinant proteins were eluted using a linear gradient of 320 
imidazole ranging from 25 mM to 250 mM over 5 column volumes (a representative SDS-321 
PAGE analysis of the eluted fractions is shown in Supplementary Figure 1A). The proteins 322 
were then further purified by gel filtration using a 10/30 Superdex 75 Increase column (Cytiva) 323 
pre-equilibrated in 20mM HEPES, 1mM EDTA, 300mM NaCl, pH 7.5. The gel filtration analysis 324 
indicated that the SARS CoV 2 Mpro protein purified as a dimer. 325 
 326 
Molecular cloning and production of SARS-CoV-2 Receptor Binding Domain protein in 327 
mammalian cells (mRBD) 328 
The cDNA region coding for the Receptor Binding Domain (RBD) (residues 334–528) 329 
defined in the structure of the S protein (PDB ID 6VSB) was amplified for expression in 330 
mammalian cells.  The fragment was cloned in frame with the IgK leader sequence, an HA-331 
tag (YPYDVPDYA) and a thrombin recognition site (LVPRGS) at its 5’ end, and it was followed 332 
by a second thrombin site, the TIM-1 mucin domain and the human IgG1 Fc region at the 3’ 333 
end.  The recombinant cDNA was cloned in a vector derived from the pEF-BOS (11) for 334 
transient expression in HEK293 cells, and in the pBJ5-GS vector for stable protein production 335 
in CHO cells following the glutamine synthetase system (12). The inclusion of the TIM-1 mucin 336 
domain enhanced protein expression. 337 
Mammalian RBD (mRBD) fused to the mucin domain and the Fc region (mRBD-338 
mucin-Fc) was initially purified from cell supernatants by affinity chromatography using an 339 
IgSelect column (GE Healthcare). The mucin-Fc portion and the HA-tag were released from 340 
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the mRBD protein by overnight treatment with thrombin at RT.  The mixture was run through 341 
a protein A column to remove the mucin-Fc protein and mRBD was further purified by size-342 
exclusion chromatography with a Superdex 75 column in HBS buffer (25 mM HEPES and 343 
150 mM NaCl, pH 7.5). The concentration of purified mRBD was determined by absorbance 344 
at 280 nm. 345 
Baculovirus production of RBD-His tagged protein 346 
A recombinant baculovirus expressing the RBD domain was generated using a 347 
pFastBac Dual-derived plasmid harboring the RBD coding sequence kindly provided by Dr. F. 348 
Krammer (6). HighFive (ThermoFisher Scientific) cell cultures were infected with the 349 
recombinant virus at a multiplicity of infection of 3 plaque forming units per cell and maintained 350 
in TC-100 medium (ThermoFisher Scientific) for 72 h. Thereafter, cell medium was harvested 351 
and clarified by centrifugation (4,300 x g for 10 min) and filtration through a 0.45 µm filter. 352 
Supernatant was loaded onto a chelated Nickel Affinity Cartridge-5ml (Agarose Bead 353 
Technologies S.L.) at a flow rate of 1.5 ml/min and eluted with a linear gradient of 500 mM 354 
Imidazole in Tris-saline buffer pH 7.5. Fractions were analyzed by SDS-PAGE and those 355 
containing RBD were pooled together and concentrated using an Amicon Ultra-15 Centrifugal 356 
unit with a 10 kDa cutoff membrane (Millipore). The concentrated protein was loaded onto a 357 
Superdex 75 10/300 Increase gel-filtration (GE Healthcare) equilibrated with PBS. The peak 358 
fractions were analyzed by SDS-PAGE and pooled together for further analysis. 359 
ELISA for detection of antibodies to SARS-CoV-2 360 
96-well Maxisorp Nunc-Immuno plate were coated with 100 μL/well of recombinant 361 
proteins diluted in 0.1 M borate buffered saline (BBS) pH 8.8; NP and the protease at 0.5 362 
μg/ml, RBD at 1μg/ml and incubated overnight at 4oC. Coating solutions were then aspirated, 363 
the ELISA plates were washed three times with 200 μl of PBS 0.05% Tween 20 (PBS-T) and 364 
then dried before blocking with PBS-casein (Biorad,1x PBS blocker) for 1 hour at room 365 
temperature. The plates were washed again with PBS-T and 100 μl of patient serum/plasma 366 
sample diluted in PBS-casein, 0.02% Tween-20, as indicated, was added and incubated for 2 367 
hours at room temperature. The plates were washed again and 100 μL/well of the indicated 368 
detection antibody [(AffiniPure Rabbit Anti-Human IgM, Fcµ fragment specific; AffiniPure 369 
Rabbit Anti-Human Serum IgA, α chain specific; AffiniPure Rabbit Anti-Human IgG, Fcγ 370 
fragment specific) from Jackson Labs, or anti-human (Fab)’2 HRPO-labelled antibody from 371 
Thermo Fisher Scientific] was added and incubated for 1 hour at room temperature. The plates 372 
were washed with PBS-T four times and incubated at room temperature in the dark with 100 373 
μL/well of Substrate Solution (OPD, Sigma prepared according to the manusfacturer’s 374 
instructions) (typically for 3 minutes). 50 μL of stop solution (3M H2SO4) were then added to 375 
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each well and the optical density (at 492nm) of each well was determined using a microplate 376 
reader. 377 
 Negative controls included wells coated just with blocking buffer and serum samples 378 
collected from donors before 2019.  379 
Statistical analysis 380 
Graphics and statistical analysis was performed with Graph Pad Prism 8 Software (GraphPad 381 
Software, USA, www.graphpad.com) and Stata 14.0 for Windows (Stata Corp LP, College 382 
Station, TX, USA). Quantitative variables following a non-normal distribution were represented 383 
as median and interquartile range (IQR) and the Mann Whitney test was used to test for 384 
statistically significant differences. Variables with a normal distribution were described by 385 
mean±standard deviation (SD) and differences between groups were assessed with Student’s 386 
t-test. Qualitative variables were described as counts and proportions and 𝟀2 or Fisher´s exact 387 
test was used for comparisons. Correlation between quantitative variables was analysed using 388 
the Pearson correlation test. 389 
Severity of COVID-19 was established as previously described (13). In this case, to determine 390 
differences in titres of antibodies between groups of severity the Cuzick’s test, that assesses 391 
trends across ordered groups, was employed.  392 
Since several variables might contribute to differences in ELISA titres, multivariable linear 393 
analysis using generalized linear models (glm command of Stata) in which the dependent 394 
variable were ELISA titres of each isotype against each protein. The first model included age, 395 
gender and time from symptoms onset, followed by backward stepwise approach removing all 396 
variables with a p value >0.15 to obtain the best model for each protein and isotype. Then, the 397 
variable of interest (severity, anosmia or IL-6 serum levels) was forced in the model. 398 
To determine the capacity of the different ELISA to discriminate between pre-COVID-19 sera 399 
and those sera obtained from patients with SARS-CoV-2, as determined by positive PCR from 400 
nasopharyngeal exudates, ROC analysis was performed, using the roctab command of Stata 401 
14.1® (College Station, Texas). Each cut-off point was selected based on the best trade-off 402 
values between sensitivity, specificity and the percentage of patients correctly classified.  ROC 403 
curves and area under curve (AUC) were also obtained. 404 
 405 
Patient samples and Institutional Review Boards 406 
This study used samples from the research project “Immune response dynamics as predictor 407 
of COVID-19 disease evolution. Implications for therapeutic decision-making” [PREDINMUN-408 
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COVID] approved by La Princesa Health Research Institute (IIS-IP) Research Ethics 409 
Committee (register # 4070). Some experiments included patients from “Study of the 410 
lymphocytic response against SARS-COV-2, in different situations of host health and COVID-411 
19 severity (InmunoCOVID)” approved by the Hospital La Paz Committee (HULP: PI-4101). 412 
All experiments were carried out following the ethical principles established in the Declaration 413 
of Helsinki. All included patients (or their representatives) were informed about the study and 414 
gave a written informed consent.  415 
Patient selection 416 
36 COVID-19 patients, diagnosed by PCR, were recruited for the study. 9 of them presented 417 
active infection by SARS-CoV2 at the moment of the study whereas the rest had no detectable 418 
levels of the virus. 10 patients required hospitalization, of which 6 were admitted to the ICU 419 
(Table 1). 33 serum samples from patients presenting a monoclonal gammopathy, allergic 420 
disease or rheumatoid arthritis, collected before June 2019 (PRE-COVID-19), were used as 421 
negative controls. All samples were stored frozen before use.  422 
 423 
Antibody detection in saliva samples 424 
 425 
12 donors with high antibody titres in serum were selected to measure specific IgG and IgA 426 
against SARS-CoV2 in saliva. For this purpose, new saliva samples were collected from these 427 
patients, and also from 11 healthy donors, aliquoted and immediately frozen. Prior to use, 428 
saliva samples were thawed, centrifuged at 400g and diluted 1/2, 1/4 and 1/10 in 1x PBS with 429 
1% casein (Bio-Rad) and 0.02% Tween-20 supplemented with Complete™ Protease Inhibitor 430 
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Table 1. Patient demographic and clinical data   501 
  N=36 % 
Gender Male 21 58 
 Female 15 42 
Age < 35 7 19 
 35-60 18 50 
 > 60 11 31 
Time from symptoms onset 
to sample collection < 15 days 2 6 
 15-30 days 13 36 
 31-45 days 14 39 
 > 45 7 19 
Hospitalization Yes Ward 4 11 
  ICU 6 17 
 No 26 72 
Fever  31 86 
Shivers 23 64 
Headache 22 61 
Confusion  6 17 
Conjunctival congestion  5 14 
Nasal congestion  18 50 
Rhinorrhea  16 44 
Anosmia  16 44 
Ageusia  18 50 
Odynophagia  14 39 
Dry cough  19 53 
Productive cough  9 25 
Dyspnea  21 58 
Chest pain  12 33 
Tonsillitis  3 8 
Adenopathies  4 11 
Nausea/vomiting  10 28 
Diarrhea  16 44 
Skin rash  2 6 
Acrocyanosis  1 3 
Myalgia/arthralgia  24 67 
Asthenia  27 75 
Weight loss  20 56 
Thrombotic events  2 6 
Comorbidities (HTN,  
DM, COPD, obesity, cancer)  17 47 
    
ICU (intensive care unit), HTN (hypertension), DM (diabetes mellitus), COPD (chronic obstructive pulmonary 502 
disease). 503 
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Table 2. AUC, cut-off, sensitivity and specificity 504 
Antigen Isotype AUC Cut-off Sensitivity Specificity 
RBD IgG 0.961 0.232 94% 97% 
IgA 0.974 0.112 97% 94% 
IgM 0.981 0.203 91% 97% 
Mpro IgG 0.994 0.161 97% 100% 
IgA 0.833 0.130 73% 100% 
IgM 0.859 0.237 79% 79% 
NP IgG 0.993 0.127 97% 100% 
IgA 0.949 0.066 88% 94% 
IgM 0.885 0.341 76% 85% 
AUC, area under the curve; RBD, Receptor Binding Domain; Mpro, cysteine-like protease; NP, nucleoprotein 505 
 506 
 507 
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Table 3. Variables that explain heterogeneity in antibody response against three proteins of 509 
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Figure legends 511 
Figure 1. SARS-CoV-2 protein purification. Nucleocapsid (NP) (A) and Cys-like protease 512 
(3CLpro, Mpro) (B) proteins were expressed in E. coli and extracted from the soluble fraction 513 
of the bacterial pellet. The proteins were firstly purified by selection through their His-tags in 514 
HiTrap Ni2+ chelating columns. The fractions eluted from these columns were run in SDS-515 
PAGE (top gels). After that, proteins were further purified by gel filtration using a Superdex 75 516 
column and fractions eluted from this step were run in SDS-PAGE (bottom gels). The FPLC 517 
profile is shown on the right panels. (C) mRBD The 334-528 fragment of the Spike protein was 518 
produced in mammalian cells fused to an HA-tag, at the N-terminus and to the TIM-1 mucin 519 
domain followed by the Fc portion of human IgG, at the C-terminus.  Two thrombin-recognition 520 
sites (asterisks) were introduced.  The fusion protein was treated with thrombin (+T in the 521 
SDS-PAGE shown at the right) to release the mRBD fragment.  It was further purified using a 522 
protein A column and size exclusion chromatography (Superdex 75).  SDS-PAGE under 523 
reducing conditions are shown for the samples at the purification steps. Proteins bound (B) 524 
and unbound (U) to the protein A column are shown. (D) SDS-PAGE. After expression in the 525 
different systems, proteins were purified and fractions from gel filtration chromatography were 526 
run in SDS-PAGE under non reducing conditions.  527 
 528 
Figure 2. Detection of SARS-CoV-2 Mpro-specific antibodies by ELISA. (A) Sera titration 529 
on Mpro. Plates were coated with SARS-CoV-2 Mpro and sera dilutions (1/50 to 1/1600) were 530 
tested. Detection was performed using anti-human F(ab)2’ antibody. (B) Isotype recognition. 531 
Plates coated with SARS-CoV-2 Mpro, nucleoprotein (NP) and RBD were detected with 532 
antibodies directed against human Ig of the three different subclasses: IgG, IgA, IgM. Black 533 
symbols correspond to COVID-19 patients and grey symbols to donors pre-COVID-19. (C) 534 
Coating titration. Plates were coated with increasing amounts of SARS-CoV-2 Mpro, 535 
nucleoprotein (NP) and RBD and sera diluted 1/100 for IgG detection and 1/50 for IgA and 536 
IgM were tested. Black symbols correspond to COVID-19 patients and grey symbols to donors 537 
pre-COVID-19. 538 
 539 
Figure 3: Comparison of sera from 33 pre-COVID-19 vs 36 COVID-19 patients. Plates 540 
coated with either 0.5 or 1 µg/ml (as indicated) SARS-CoV-2 Mpro, NP or RBD were used to 541 
perform ELISA tests on 36 COVID-19 positive and 33 negative control sera (obtained before 542 
the pandemic outbreak, PRE-COVID-19). Detection was done using antibodies directed 543 
against human immunoglobulin of the three different subclasses: IgG, IgA, IgM. Sera dilutions 544 
from 1/50-1/3200 were carried out. Data were normalised for each antigen using the signal 545 
obtained against a pool of positive sera. Box and whisker plots of all the sera tested at the 546 
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1/200 dilution for IgG and 1/50 for IgA and IgM. Statistical significance was analysed in Mann-547 
Whitney tests. **** means p<0.0001.  548 
 549 
Figure 4: Assessment, through Receiver Operating Characteristic (ROC) analysis, of 550 
different isotype responses against three SARS-CoV-2 proteins as COVID-19 551 
classifiers. Graphic representation of the relationship between sensitivity and specificity. The 552 
area under the curve (AUC) calculated for each antigen and immunoglobulin pair (see 553 
Statistical section of Material and Methods) is indicated. For details on specificity and 554 
sensitivity data, see Supplementary Table 1.  555 
 556 
Figure 5. A. Correlations of humoral response against different SARS-CoV-2 557 
antigens by isotype. Data from Figure 2 are shown as dot-plots and their fitted 558 
fractional polynomial prediction with 95% confidence interval (transparent grey 559 
shadow) estimated using the two-way command of Stata with the fpfitci option. B. 560 
Comparison of sera from mild, severe and critical patients. Patients were classified into 561 
three groups (mild n=13, severe n=17 and critical n=6) according to COVID-19 symptoms 562 
severity (see reference 13). Data normalised for each antigen using the signal obtained 563 
against a pool of positive sera obtained in Figure 2, are depicted in box and whisker plots at 564 
the 1/200 dilution for IgG and 1/50 for IgA and IgM. Statistical significance was analysed by 565 
Cuzick’s test. 566 
 567 
Figure 6. No cross-reactivity is observed between proteins from SARS-Cov-2 and OC43 568 
betacoronaviruses. Plates were coated with 0.5 μg/ml of either SARS-CoV-2 NP or OC43 569 
NP as indicated. Sera collected before 2020 (Pre-COVID-19) were tested at a 1/100 dilution. 570 
Detection was performed using antibody directed against human IgG. The bars labelled “2721-571 
0848” correspond to COVID-19 PCR+ sera; the wells in which the amount of coated protein 572 
was tested by incubation with either anti-His are indicated. 13 out of 20 (65%) pre-COVID sera 573 
and 4 out of 7 (57%) COVID-19+ were clearly seropositive for OC43 NP. The donors with 574 
higher titres for OC43 anti-NP antibodies do not respond against SARS-NP, indicating that 575 
prior infection with OC43 does not lead to generation of antibodies reactive with SARS-CoV-576 
2 antigens. 577 
 578 
Figure 7: Comparison of saliva from healthy donors and 12 COVID-19 seropositive 579 
individuals. Plates coated with either 0.5 µg/ml of SARS-CoV-2 Mpro and NP or 1 µg/ml of 580 
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RBD and ELISA tests were carried out on saliva samples diluted 1/2 to 1/10. Detection was 581 
done using antibodies directed against human IgG. Data were normalised for each antigen 582 
using the signal obtained for the positive control histidine-tag. Mann-Whitney test was 583 
performed to compare the values obtained for each dilution in healthy donors and patients. ** 584 
p<0.01, **** p<0.0001. 585 
 586 
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Figure 1
A. NP B. Mpro
C. mRBD
RNA-binding Dimerisation HHHHHH HHHHHH
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Figure 2
A. ELISA. Coating Mpro / Detection anti-h F(ab)2’
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Mpro Mpro Mpro
C. Coating titration Figure 2
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RBD (1 µg/ml)  
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Figure 4
RBD (1 µg/ml)  
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Figure 6
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Figure 7
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Supplementary Figure 1
Supplementary Figure 1. Detection of SARS-CoV-2 RBD-specific antibodies by ELISA. Plates were coated with 
SARS-CoV-2 RBD proteins produced in eukaryotic systems, either using insect or mammalian cells, and sera 
dilutions (1/100 to 1/1600) were tested. Detection was performed using anti-human IgG antibody. Black 
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Supplementary Figure 2
Supplementary Figure 2. Background levels and negative ontrols. A. Background in plates with no viral 
protein coating. Plates were coated with 1 μg/ml of SARS-CoV-2 Mpro or iRBD and different dilutions of 
patient sera, as indicated, and detected with anti-human F(ab)2’ antibody (left and middle panels). Casein 
control corresponds to wells coated with the blocking solution, containing casein (right). These wells were 
incubated with the same sera and developed with anti-human F(ab)2’ antibody to check the background 
corresponding to individual sera.  B. SARS-CoV-2 negative controls. 24 sera collected before 2020 (Pre-
COVID-19) were tested in plates coated with 1 μg/ml of SARS-CoV-2 Mpro or NP. Sera were added at a 1/50-
1/900 dilution. Detection was performed using antibodies directed against human IgG or IgM. Data from the 
1/50 dilution are shown for IgM and 1/200 for IgG. Serum number 0850 corresponds to a positive control 
serum.
A. Serum background in plates coated with casein (no viral protein)
B. Sera collected before 2020 (pre-COVID-19)
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Supplementary Figure 3: Comparisons between different sera dilutions for RBD,
Mpro and NP. Plates coated with SARS-CoV-2 Mpro, NP or RBD were used to perform
ELISA tests on 36 COVID-19 positive and 33 negative control sera. Detection was done
using antibodies directed against human immunoglobulin of the three different
subclasses: dilutions 1/50-1/3200 were used for IgG; dilutions 1/50-1/1350 were used for
IgA and IgM. Graphs represent data of the ODs obtained for each antigen and each
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A. Aminoacid alignment of Mpro from different human coronaviruses
Supplementary Figure 4
Supplementary Figure 4. Alignment of Mpro amino acid sequences from the indicated 
coronaviruses. Sequences were obtained from the NCBI database and aligned using the
Clustal Omega program (https://www.ebi.ac.uk/Tools/msa/clustalo/). * indicates 
positions which have a single, fully conserved residue, : indicates strong similarity, . 
indicates weak similarity.
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